Press Releases
- Featured Highlights Press Press ReleasesPartnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate ROCKVILLE, Md. & CARLSBAD, Calif.--(BUSINESS WIRE)-- Immunomic Therapeutics,Read more
ITI CEO to present at BIO CEO & Investor Digital Conference
Featured Press Press ReleasesFebruary 02, 2021 08:05 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the BIORead moreImmunomic Therapeutics’ CEO to present at the 13th Annual Biotech Showcase Digital Event
Featured Press Press ReleasesJanuary 05, 2021 08:05 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 13th AnnualRead more- Featured Press Press ReleasesDecember 09, 2020 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, and WhyWeVax™ (WWV),Read more
ITI’s CEO to Present at the 2nd Annual Glioblastoma Drug Development Summit
Featured Highlights Press Press ReleasesDecember 01, 2020 08:05 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that it will be presenting at the 2nd Annual Glioblastoma Drug Development Virtual Summit.Read moreITI and CoImmune Enter into Partnership to Manufacture A Novel Experimental Cell Therapy for GBM
Featured Highlights Press Press ReleasesNovember 19, 2020 04:05 PM Eastern Standard Time ROCKVILLE, Md. & DURHAM, N.C.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms,Read moreITI to Present at SITC’s 35th Anniversary Annual Meeting & Pre-Conference Programs
Featured Press Press Releases-Data from preclinical studies demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses in mice- November 02, 2020 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics,Read moreITI Announces Promotion of Dr. Tim Coleman to SVP, Operations and GM
Press Press ReleasesOct. 22, 2020 12:00 UTC Immunomic Therapeutics Announces Promotion of Dr. Tim Coleman to Senior Vice President, Operations and General Manager ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately-heldRead moreITI CEO to Present at the 5th International Virtual Conference on Cancer Research & Development 2020
Press ReleasesOctober 20, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that it will be presenting at the 5th International Virtual Conference on Cancer Research &Read moreITI’s CEO to Participate in Panel at MD Life Sciences’ Bio Innovation Conference Meeting 2020
Featured Press Press ReleasesSeptember 29, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate in a panel at the MD Life Sciences Bio InnovationRead moreITI’s VP to Participate at Precision Medicine’s Webinar on Oncolytic Therapeutic Development
Featured Highlights Press Press ReleasesSeptember 23, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will be participating in Precision Medicine’s webinar on utilizing liquid biopsy toRead moreITI to Participate at World Vaccine Congress Washington 2020
Featured Press Press ReleasesROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020. Andrew Eisen, MD, Ph.D.,Read more